CyNRGY™ Platform

RRx-001  ·  Inflammasome   ·  Oncology

View Publications
The CyNRGY platform represents a novel class of multi-faceted anti-inflammatory compounds with ground-breaking broad-spectrum applications under evaluation in late-stage oncology clinical trials as well as pre-clinical studies in several neurodegenerative conditions.
orange line and dot

RRx-001 Oncology Program

Preliminary data suggest that patients pretreated with RRx-001 before common chemotherapeutics or radiation therapy, experience less new malignancies, tumor recurrences or certain prevalent side-effects such as severe oral mucositis and neutropenia.

Normally, side effects from many oncology medications lead to discontinuation, dose reduction, non-compliance, delays, and pipeline development terminations. In cancer, improved outcomes are related to dose intensity (DI), where patients that receive higher dose intensities experience better overall survival (OS), progression-free survival (PFS), and disease-free survival than patients that receive lower DI levels. Clinical studies suggest that as an NLRP3 inflammasome inhibitor RRx-001 may not only increase the activity of chemotherapy, radiotherapy, and immunotherapy but also decrease their various toxicities including checkpoint inhibitor induced colitis.

Protection indications are currently being evaluated in clinical trials, demonstrating potential utility of RRx-001 in reducing the harmful and debilitating side effects of effective yet toxic treatments like radiotherapy and chemotherapy.

Anti-tumor Mechanism of RRx-001

RRx-001, is a multifaceted small molecule inflammasome NLRP3/KEAP1 inhibitor with tumor-targeted cytotoxicity and healthy tissue cytoprotective properties. RRx-001 was selected based on its dual-functioning mechanism that protects healthy tissue under “normal” oxygenation conditions but is also activated under hypoxia to destabilize the tumor micro-environment. After intravenous infusion, RRx-001 is carried to the tumor microenvironment by red blood cells and macrophages to stimulate M2-to-M1 polarization while promoting antioxidant and anti-inflammatory properties through induction of the Nrf2 protein and inhibition of the inflammasome. The antioxidation activity, combined with the anti-inflammatory inflammasome inhibition, supports a protection mechanism in healthy tissues.

The Inflammasome

Regulating chronic inflammation

Chronic inflammation is a hallmark of most major diseases including cancer. Inflammation is a “double-edged sword” that, on the one hand, augments antitumor immunity, and on the other, dampens it through upregulation of immune checkpoints and anti-inflammatory cytokines. The NLRP3 inflammasome, which kickstarts and perpetuates the inflammatory response through the production of the pro-inflammatory cytokines, IL-1β, and IL-18, plays a central role in cancer.

“RRx-001 inhibition of the inflammasome represents an exciting potential in the treatment and prevention of chronic inflammation driven diseases”

Preclinical studies are underway in hopes of unlocking this potential and addressing a long list of inflammation (inflammasome) regulated disorders with a persisting unmet medical need.

RICHARD GORDON, Ph.D., DABT
Chief Neuroscience Collaborator

BIO

The neuroprotective effects of RRx-001

With funding from The Michael J. Fox Foundation for Parkinson’s Research and Shake it Up Australia, we’re exploring how RRx-001’s inhibition of the inflammasome may reduce or reverse symptoms of Parkinson’s and other neurodegenerative diseases. Led by Dr. Richard Gordon at The University of Queensland in Brisbane, Australia, this collaboration studies how RRx-001 binds to cysteines found in immune and red blood cells, promoting protective cellular responses through induction of the Nrf2 pathway and inhibition of the NLRP3 inflammasome.

TONY REID, M.D. Ph.D.

Chief Executive Officer & Chief Scientific Office

BIO

FRANCK BRINKHAUS, Ph.D.

Chief Financial Officer

BIO

BRYAN ORONSKY, M.D. Ph.D.

Chief Medical Officer

BIO

CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

BIO

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

BIO

SCOTT CAROEN
Senior Director of Operations & Corporate Development

BIO

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

BIO

Control inflammation & control the disease

RRx-001 inhibits the inflammasome

The Inflammasome is responsible for activation of inflammatory responses. With chronic inflammation tissue destruction that occurs outpaces the regeneration of damaged tissues. Eventually, over time, the normal function of these tissues is reduced or lost. In chronically inflamed tissues, which may result from unresolved sources of foreign bodies, irritants or infections, the inflammasome fuels an inflammatory response for weeks to months or even years, resulting in a range of metabolic, neurological, autoimmune disorders as well as in the initiation of cancer.
The Answer: AdAPT-001 programs infected cancer cells to produce a TGFβ “trap” molecule that is designed to neutralize TGFβ within the infected tumor. Eliminating the t-cell silencing TGFβ protein allows for the immune system to remain activated against cancer, making AdAPT-001 unlike any other immunotherapy.
AdAPT-001 doesn’t just create a cancer targeted infection, it produces a proprietary TGFβ “trap” protein to eliminate this tumor defense mechanism and allow for sustained immune response against cancer – alone or in combination with immune checkpoint inhibitors.

TONY REID, M.D. Ph.D.

Chief Executive Officer & Chief Scientific Office

BIO

FRANCK BRINKHAUS, Ph.D.

Chief Financial Officer

BIO

BRYAN ORONSKY, M.D. Ph.D.

Chief Medical Officer

BIO

CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

BIO

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

BIO

SCOTT CAROEN
Senior Director of Operations & Corporate Development

BIO

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

BIO

Control inflammation & control the disease

RRx-001 inhibits the inflammasome

The Inflammasome is responsible for activation of inflammatory responses. With chronic inflammation tissue destruction that occurs outpaces the regeneration of damaged tissues. Eventually, over time, the normal function of these tissues is reduced or lost. In chronically inflamed tissues, which may result from unresolved sources of foreign bodies, irritants or infections, the inflammasome fuels an inflammatory response for weeks to months or even years, resulting in a range of metabolic, neurological, autoimmune disorders as well as in the initiation of cancer.
The Answer: AdAPT-001 programs infected cancer cells to produce a TGFβ “trap” molecule that is designed to neutralize TGFβ within the infected tumor. Eliminating the t-cell silencing TGFβ protein allows for the immune system to remain activated against cancer, making AdAPT-001 unlike any other immunotherapy.
AdAPT-001 doesn’t just create a cancer targeted infection, it produces a proprietary TGFβ “trap” protein to eliminate this tumor defense mechanism and allow for sustained immune response against cancer – alone or in combination with immune checkpoint inhibitors.

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital